comprehensive -WSS

comprehensive

author：comprehensive 2025-10-02 22:58:18 - browse：67342

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Advisers to the Food and Drug Administration voted 11-0 on Monday to recommend the approval of a drug for early Alzheimer’s disease made by Eli Lilly — ruling that the treatment’s ability to slow the cognitive decline in patients outweighed its safety risks.

The unanimous outcome of the daylong advisory panel was the best-case scenario for Lilly, making it likely that the FDA will approve the drug, called donanemab, for a broad population of people diagnosed with mild cognitive impairment due to Alzheimer’s. A decision is expected later this year.

“The benefits outweigh the risks, as long as the risks are being monitored,” said Kathleen Poston, a neurologist at Stanford University and a member of the advisory panel.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Faced with fears of OxyContin misuse, sales reps touted its safety

hotspot

WSS

Maui funeral service workers on devastation of fires: 'I'm in shock'

Faced with fears of OxyContin misuse, sales reps touted its safety

Novo acquires Inversago for up to $1 billion

What the airline industry can learn from medicine

Large hospital system sues Multiplan for low

An innovative path out of biotech’s “valley of death”

entertainment

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Medical records are filled with copy

Newly revealed memo details efforts to keep Trump in power following election loss

Walensky prepares to leave CDC — and Congress — behind

House GOP releases memo on Hunter Biden foreign business dealings, reviving old claims

Sports medicine is finally prioritizing gender equality

Kim Kardashian sparks debate on benefits of full

State Dept. review finds Biden bears some blame for Afghanistan failures

5 important ways Henrietta Lacks changed medical science

Moonlake's readout produced a cash windfall. Risks remain

EQRx, failed developer of low

entertainment

What the US credit downgrade means for the economy, your finances

‘Oppenheimer’ and the risks of AI in health care

GOP presidential candidates start declaring their loyalty

Some of the ways extreme heat will change life as we know it

Vertex non

CDC overhauls leadership of center that led response to Covid

knowledge

hotspot

Wikipedia

hotspot